Picture of Cosmo Pharmaceuticals NV logo

COPN Cosmo Pharmaceuticals NV Share Price

0.000.00%
ch flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Momentum

Relative Strength (%)
1m-8.3%
3m-18.76%
6m-9.38%
1yr+33.66%
Volume Change (%)
10d/3m-6.16%
Price vs... (%)
52w High-21.96%
50d MA-9.69%
200d MA-11.85%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)10.77
PEG Ratio (f)n/a
EPS Growth (f)-13.08%
Dividend Yield (f)1.83%
Valuation (ttm)IndustryMarket
Price to Book Value2.17
Price to Tang. Book10.84
Price to Free Cashflow11.07
Price to Sales5.85
EV to EBITDA9.53

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital14.32%
Return on Equity14.97%
Operating Margin46.38%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Cosmo Pharmaceuticals NV EPS forecast chart

Profile Summary

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.

Directors

Last Annual
December 31st, 2023
Last Interim
June 30th, 2024
Incorporated
January 1st, 1970
Public Since
May 18th, 2016
No. of Employees
339
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ch flag iconSIX Swiss Exchange
Shares in Issue
16,045,886

COPN Share Price Performance

Upcoming Events for COPN

Cosmo Pharmaceuticals NV Annual Shareholders Meeting

Similar to COPN

Picture of Curatis Holding AG logo

Curatis Holding AG

ch flag iconSIX Swiss Exchange

Picture of Dottikon Es Holding AG logo

Dottikon Es Holding AG

ch flag iconSIX Swiss Exchange

Picture of Galenica AG logo

Galenica AG

ch flag iconSIX Swiss Exchange

Picture of Novartis AG logo

Novartis AG

ch flag iconSIX Swiss Exchange

Picture of PolyPeptide AG logo

PolyPeptide AG

ch flag iconSIX Swiss Exchange

FAQ